【2h】

Renal recovery

机译:肾脏恢复

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Acute kidney injury (AKI) research in the past decade has mostly focused upon development of a standard AKI definition, validation of early novel biomarkers to predict AKI prior to serum creatinine rise and predict AKI severity, and assessment of aspects of renal replacement therapies and their impact on survival. Given the independent association between AKI and mortality in the acute phase, such focus makes imminent sense. More recently, the recognition that AKI is associated with subsequent development of chronic kidney disease and end-stage renal disease, with the attendant increase in mortality, has led to interest in the clinical epidemiology and the mechanistic understanding of renal recovery after an AKI episode in critically ill patients. We review the current knowledge surrounding renal recovery after an AKI episode, including renal replacement therapy initiation timing and modality impact, biomarker assessment and mechanistic targets to guide potential future clinical trials.
机译:过去十年中的急性肾损伤(AKI)研究主要集中在标准AKI定义的开发,早期新型生物标志物的验证以预测血清肌酐升高之前的AKI和预测AKI的严重性以及评估肾脏替代疗法及其方面对生存的影响。鉴于急性期AKI与死亡率之间的独立关联,这种关注迫在眉睫。最近,人们认识到AKI与慢性肾脏病和终末期肾脏疾病的继发发展以及随之而来的死亡率增加有关,这引起了人们对AKI发作后临床流行病学和对肾脏恢复的机理的了解。危重病人。我们回顾了AKI发作后有关肾脏恢复的当前知识,包括肾脏替代治疗的开始时间和方式影响,生物标志物评估以及旨在指导潜在的未来临床试验的机制指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号